AstraZeneca (AZN) Announces Positive Data from Fostamatinib in Patients with RA Who Didn't Respond to MTX
Tweet Send to a Friend
AstraZeneca's (NYSE: AZN) announced that fostamatinib (R788) showed improved results in patients with rheumatoid arthritis (RA) who responded inadequately ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
